The COVID-19 Pandemic: Defining the Clinical Syndrome and Describing an Empirical Response


  • Mandalam Seshadri Thirumalai Mission Hospital
  • T. Jacob John Christian Medical College, Vellore, India



COVID-19, clinical syndrome, empiric therapy, hydroxychloroquine


The novel corona virus infectious disease, COVID-19, is a pandemic now and is raging through several continents, posing a challenge to health-care systems of all the countries and disrupting lives and livelihoods across the world. The facilities for virus testing are available for only limited numbers in each country and each country excludes a large number of potentially infected subjects because the lab test is done for only certain categories. Nearly 80 % of those infected will therefore go undiagnosed. There is an urgent need therfore to define the clinical syndrome so that practitioners at the primary and secondary levels can make a confident clinical diagnosis and proceed to manage patients early and effectively. Chloroquine and hydroxychloroquine, both antimalarials have shown promise in limited trials in France and China. They are inexpensive, have been around for several decades in the prevention and treatment of malaria, have well-known side-effects and in the short term safe for use . We propose that practitioners make a preliminary clinical diagnosis of the COVID-19 syndrome based on simple clinical criteria and  lab tests and proceed to manage patients and protect other family members and contacts by using isolation measures and short regimens of these anti malarial and other medications, anticipating results of more clinical trials.

Author Biographies

Mandalam Seshadri, Thirumalai Mission Hospital

MD, PhD, FRCP(Edinburgh)
Former Professor of Medicine, CMC Hospital , Vellore

Consultant Physician, Endocrinologist & Honorary Medical Director
Thirumalai Mission Hospital,Thirumalainagar
Vanapadi Road
Ranipet 632404

T. Jacob John, Christian Medical College, Vellore, India

Former Professor & Head, Department of Clinical Virology

Christian Medical College, Vellore, India 632004


Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, St. George K, et al. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: value of diagnostic testing for SARS-CoV-2/COVID-19. 2020. mBio 11:e00722-20. Available from:

Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent J-L. Sepsis and septic shock. Nat Rev Dis Primers. 2017;2:16045.

World Health Organization. Health topics: Coronavirus [Internet]. Available from:

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,Wet al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020. 323:1061-69.

Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clinical Infectious Diseases. 2020 Mar 26;ciaa330.

Ren X, Liu Yan, Chen, H, Liu W, Guo Z, zhang y, et al. Application and optimization of RT-PCR in diagnosis of SARS-CoV-2 infection. Preprints with The Lancet. 2020 Mar 3.

Thomas J. The flu: facts, statistics, and you [Internet]. Healthline. 2018 Nov 19. Available from:

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 2020 Mar 20:105949. [Epub ahead of print].

Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome, Clinical Research & Reviews PII. S1871-4021(20)30051-5.

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Diseases. 2003.3:722-7.

Yazdany J,Kim AHJ. Use of hydroxychloroquine and chloroquine during the Covid-19 pandemic: what every clinician should know. Annals Intern Med. 2020.

WHO. Global research on coronavirus disease (COVID-19)/ “Solidarity” clinical trial for COVID-19 treatments [Internet]. Available from:

Indian Council of Medical Research, National Task Force for COVID-19. Advisory on the use of hydroxyl-chloroquine as prophylaxis for SARS-CoV-2 infection [Internet]. Available from:

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020 Mar 9;ciaa237.

Aartjan JW, te Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathogens. 2020 Nov.

Jing Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding W-Q. Chloroquine is a zinc ionophore. PLoS ONE 9(10): e109180.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J,et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS. 2020 Apr 6.

Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med. 2004;350:1118-29.




How to Cite

Seshadri, M., & John, J. (2020). The COVID-19 Pandemic: Defining the Clinical Syndrome and Describing an Empirical Response. Christian Journal for Global Health, 7(1), 37–44.